Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients
Identifieur interne : 001C78 ( PascalFrancis/Curation ); précédent : 001C77; suivant : 001C79Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients
Auteurs : Nathalie Dhedin [France] ; Anne Krivine [France] ; Nicole Le Corre [France] ; Alain Mallet [France] ; Bruno Lioure [France] ; Jacques-Olivier Bay [France] ; Marie-Thérèse Rubio [France] ; Philippe Agape [Réunion] ; Anne Thiebaut [France] ; Jérôme Le Goff [France] ; Brigitte Autran [France] ; Patricia Ribaud [France]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin, Cellule souche, Vaccination.
English descriptors
- KwdEn :
Abstract
Background: The present study evaluated immunogenicity and tolerance of two-dose influenza A/H1N1pdm09 vaccination in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and compared the vaccine-induced humoral response to that triggered by natural infection in another group of HSCT patients. Methods: Adult allogeneic HSCT recipients vaccinated with two doses of influenza A/H1N1pdm09 vaccine, separated by 3 weeks, and patients with proven influenza A/H1N1pdm09 infection were included. Antibody responses were measured by hemagglutination-inhibition assay 1) on days 0, 21, 42 and 6 months after the first vaccine injection in vaccinated patients and 2) before pandemic and after influenza A/H1N1pdm09 infection, in patients presented natural infection. Results: At baseline, 3% of 59 recipients of adjuvanted vaccine and 0% of 20 infected patients were seroprotected (antibody titer ≥ 1/40). Seroprotection rate observed 42 days after vaccination was not different from that observed after natural infection (66% and 60% respectively, p = 0.78). In vaccinated patients, seroprotection rate increased significantly from 54% to 66% between day 21 and 42 (p = 0.015). Moreover, after 6 months, seroprotection rate in 21 vaccinated patients was similar to that observed in 10 infected patients evaluated at least 76 days after infection (D76-217) (60% and 81% respectively, p = 0.2). In multivariate analysis, no immunosuppressive treatment or chronic graft-versus-host disease (GVHD) and longer time between transplantation and vaccination/infection were associated with a stronger humoral response. The adjuvanted vaccine was safe with low rate of GVHD worsening. Conclusion: In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000140
Links to Exploration step
Pascal:14-0076696Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients</title><author><name sortKey="Dhedin, Nathalie" sort="Dhedin, Nathalie" uniqKey="Dhedin N" first="Nathalie" last="Dhedin">Nathalie Dhedin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service d'Hématologie-Adolescents Jeunes Adultes, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Service d'Hématologie, Groupe Hospitalier Pitié Salpêtrière, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Krivine, Anne" sort="Krivine, Anne" uniqKey="Krivine A" first="Anne" last="Krivine">Anne Krivine</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Service de Virologie, Hôpital Saint-Vincent-de-Paul Cochin, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Le Corre, Nicole" sort="Le Corre, Nicole" uniqKey="Le Corre N" first="Nicole" last="Le Corre">Nicole Le Corre</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>UPMC Université Paris 06, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Mallet, Alain" sort="Mallet, Alain" uniqKey="Mallet A" first="Alain" last="Mallet">Alain Mallet</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Unité de Recherche Clinique, Groupe Hospitalier Pitié Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Lioure, Bruno" sort="Lioure, Bruno" uniqKey="Lioure B" first="Bruno" last="Lioure">Bruno Lioure</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Département d'Hématologie, Hôpitaux Universitaires Strasbourg</s1><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Bay, Jacques Olivier" sort="Bay, Jacques Olivier" uniqKey="Bay J" first="Jacques-Olivier" last="Bay">Jacques-Olivier Bay</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Service d'Hématologie, Centre Hospitalier-Universitaire Estaing</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Rubio, Marie Therese" sort="Rubio, Marie Therese" uniqKey="Rubio M" first="Marie-Thérèse" last="Rubio">Marie-Thérèse Rubio</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Service d'Hématologie, Hôpital Saint-Antoine, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Agape, Philippe" sort="Agape, Philippe" uniqKey="Agape P" first="Philippe" last="Agape">Philippe Agape</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Service d'Hématologie et d'Oncologie médicale. Centre Hospitalier Universitaire de la Réunion. Hôpital Felix Guyon</s1><s2>Saint Denis</s2><s3>REU</s3><sZ>8 aut.</sZ></inist:fA14><country>Réunion</country></affiliation></author><author><name sortKey="Thiebaut, Anne" sort="Thiebaut, Anne" uniqKey="Thiebaut A" first="Anne" last="Thiebaut">Anne Thiebaut</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Service d'Hématologie, Hôpital Michallon</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Le Goff, Jerome" sort="Le Goff, Jerome" uniqKey="Le Goff J" first="Jérôme" last="Le Goff">Jérôme Le Goff</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Service de virologie, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Université Paris-Diderot, Sorbonne Paris, Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Autran, Brigitte" sort="Autran, Brigitte" uniqKey="Autran B" first="Brigitte" last="Autran">Brigitte Autran</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>UPMC Université Paris 06, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Ribaud, Patricia" sort="Ribaud, Patricia" uniqKey="Ribaud P" first="Patricia" last="Ribaud">Patricia Ribaud</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Université Paris-Diderot, Sorbonne Paris, Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0076696</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0076696 INIST</idno><idno type="RBID">Pascal:14-0076696</idno><idno type="wicri:Area/PascalFrancis/Corpus">000140</idno><idno type="wicri:Area/PascalFrancis/Curation">001C78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients</title><author><name sortKey="Dhedin, Nathalie" sort="Dhedin, Nathalie" uniqKey="Dhedin N" first="Nathalie" last="Dhedin">Nathalie Dhedin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Service d'Hématologie-Adolescents Jeunes Adultes, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Service d'Hématologie, Groupe Hospitalier Pitié Salpêtrière, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Krivine, Anne" sort="Krivine, Anne" uniqKey="Krivine A" first="Anne" last="Krivine">Anne Krivine</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Service de Virologie, Hôpital Saint-Vincent-de-Paul Cochin, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Le Corre, Nicole" sort="Le Corre, Nicole" uniqKey="Le Corre N" first="Nicole" last="Le Corre">Nicole Le Corre</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>UPMC Université Paris 06, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Mallet, Alain" sort="Mallet, Alain" uniqKey="Mallet A" first="Alain" last="Mallet">Alain Mallet</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Unité de Recherche Clinique, Groupe Hospitalier Pitié Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Lioure, Bruno" sort="Lioure, Bruno" uniqKey="Lioure B" first="Bruno" last="Lioure">Bruno Lioure</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Département d'Hématologie, Hôpitaux Universitaires Strasbourg</s1><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Bay, Jacques Olivier" sort="Bay, Jacques Olivier" uniqKey="Bay J" first="Jacques-Olivier" last="Bay">Jacques-Olivier Bay</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Service d'Hématologie, Centre Hospitalier-Universitaire Estaing</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Rubio, Marie Therese" sort="Rubio, Marie Therese" uniqKey="Rubio M" first="Marie-Thérèse" last="Rubio">Marie-Thérèse Rubio</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Service d'Hématologie, Hôpital Saint-Antoine, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Agape, Philippe" sort="Agape, Philippe" uniqKey="Agape P" first="Philippe" last="Agape">Philippe Agape</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Service d'Hématologie et d'Oncologie médicale. Centre Hospitalier Universitaire de la Réunion. Hôpital Felix Guyon</s1><s2>Saint Denis</s2><s3>REU</s3><sZ>8 aut.</sZ></inist:fA14><country>Réunion</country></affiliation></author><author><name sortKey="Thiebaut, Anne" sort="Thiebaut, Anne" uniqKey="Thiebaut A" first="Anne" last="Thiebaut">Anne Thiebaut</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Service d'Hématologie, Hôpital Michallon</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Le Goff, Jerome" sort="Le Goff, Jerome" uniqKey="Le Goff J" first="Jérôme" last="Le Goff">Jérôme Le Goff</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Service de virologie, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Université Paris-Diderot, Sorbonne Paris, Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Autran, Brigitte" sort="Autran, Brigitte" uniqKey="Autran B" first="Brigitte" last="Autran">Brigitte Autran</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>UPMC Université Paris 06, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>INSERM, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Ribaud, Patricia" sort="Ribaud, Patricia" uniqKey="Ribaud P" first="Patricia" last="Ribaud">Patricia Ribaud</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Université Paris-Diderot, Sorbonne Paris, Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14><country>France</country></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Hematopoietic cell</term><term>Humoral immunity</term><term>Immune response</term><term>Immunological adjuvant</term><term>Influenza A</term><term>Recipient</term><term>Stem cell</term><term>Transplantation</term><term>Vaccination</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Immunité humorale</term><term>Adjuvant immunologique</term><term>Vaccin</term><term>Cellule souche</term><term>Receveur</term><term>Vaccination</term><term>Cellule hématopoïétique</term><term>Transplantation</term><term>Grippe A</term><term>Réponse immune</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term><term>Cellule souche</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: The present study evaluated immunogenicity and tolerance of two-dose influenza A/H1N1pdm09 vaccination in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and compared the vaccine-induced humoral response to that triggered by natural infection in another group of HSCT patients. Methods: Adult allogeneic HSCT recipients vaccinated with two doses of influenza A/H1N1pdm09 vaccine, separated by 3 weeks, and patients with proven influenza A/H1N1pdm09 infection were included. Antibody responses were measured by hemagglutination-inhibition assay 1) on days 0, 21, 42 and 6 months after the first vaccine injection in vaccinated patients and 2) before pandemic and after influenza A/H1N1pdm09 infection, in patients presented natural infection. Results: At baseline, 3% of 59 recipients of adjuvanted vaccine and 0% of 20 infected patients were seroprotected (antibody titer ≥ 1/40). Seroprotection rate observed 42 days after vaccination was not different from that observed after natural infection (66% and 60% respectively, p = 0.78). In vaccinated patients, seroprotection rate increased significantly from 54% to 66% between day 21 and 42 (p = 0.015). Moreover, after 6 months, seroprotection rate in 21 vaccinated patients was similar to that observed in 10 infected patients evaluated at least 76 days after infection (D76-217) (60% and 81% respectively, p = 0.2). In multivariate analysis, no immunosuppressive treatment or chronic graft-versus-host disease (GVHD) and longer time between transplantation and vaccination/infection were associated with a stronger humoral response. The adjuvanted vaccine was safe with low rate of GVHD worsening. Conclusion: In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0></fA01><fA02 i1="01"><s0>VACCDE</s0></fA02><fA03 i2="1"><s0>Vaccine</s0></fA03><fA05><s2>32</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients</s1></fA08><fA11 i1="01" i2="1"><s1>DHEDIN (Nathalie)</s1></fA11><fA11 i1="02" i2="1"><s1>KRIVINE (Anne)</s1></fA11><fA11 i1="03" i2="1"><s1>LE CORRE (Nicole)</s1></fA11><fA11 i1="04" i2="1"><s1>MALLET (Alain)</s1></fA11><fA11 i1="05" i2="1"><s1>LIOURE (Bruno)</s1></fA11><fA11 i1="06" i2="1"><s1>BAY (Jacques-Olivier)</s1></fA11><fA11 i1="07" i2="1"><s1>RUBIO (Marie-Thérèse)</s1></fA11><fA11 i1="08" i2="1"><s1>AGAPE (Philippe)</s1></fA11><fA11 i1="09" i2="1"><s1>THIEBAUT (Anne)</s1></fA11><fA11 i1="10" i2="1"><s1>LE GOFF (Jérôme)</s1></fA11><fA11 i1="11" i2="1"><s1>AUTRAN (Brigitte)</s1></fA11><fA11 i1="12" i2="1"><s1>RIBAUD (Patricia)</s1></fA11><fA14 i1="01"><s1>Service d'Hématologie-Adolescents Jeunes Adultes, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Service d'Hématologie, Groupe Hospitalier Pitié Salpêtrière, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>Service de Virologie, Hôpital Saint-Vincent-de-Paul Cochin, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>UPMC Université Paris 06, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="05"><s1>INSERM, UMR S 945, Laboratory Immunity and Infection</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ><sZ>11 aut.</sZ></fA14><fA14 i1="06"><s1>Unité de Recherche Clinique, Groupe Hospitalier Pitié Salpêtrière</s1><s2>Paris</s2><s3>FRA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="07"><s1>Département d'Hématologie, Hôpitaux Universitaires Strasbourg</s1><s3>FRA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="08"><s1>Service d'Hématologie, Centre Hospitalier-Universitaire Estaing</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="09"><s1>Service d'Hématologie, Hôpital Saint-Antoine, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="10"><s1>Service d'Hématologie et d'Oncologie médicale. Centre Hospitalier Universitaire de la Réunion. Hôpital Felix Guyon</s1><s2>Saint Denis</s2><s3>REU</s3><sZ>8 aut.</sZ></fA14><fA14 i1="11"><s1>Service d'Hématologie, Hôpital Michallon</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="12"><s1>Service de virologie, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="13"><s1>Université Paris-Diderot, Sorbonne Paris, Cité</s1><s2>Paris</s2><s3>FRA</s3><sZ>10 aut.</sZ><sZ>12 aut.</sZ></fA14><fA14 i1="14"><s1>Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis, AP-HP</s1><s2>Paris</s2><s3>FRA</s3><sZ>12 aut.</sZ></fA14><fA20><s1>585-591</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289</s2><s5>354000505797480090</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>38 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0076696</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: The present study evaluated immunogenicity and tolerance of two-dose influenza A/H1N1pdm09 vaccination in allogeneic hematopoietic stem cell transplantation (HSCT) recipients, and compared the vaccine-induced humoral response to that triggered by natural infection in another group of HSCT patients. Methods: Adult allogeneic HSCT recipients vaccinated with two doses of influenza A/H1N1pdm09 vaccine, separated by 3 weeks, and patients with proven influenza A/H1N1pdm09 infection were included. Antibody responses were measured by hemagglutination-inhibition assay 1) on days 0, 21, 42 and 6 months after the first vaccine injection in vaccinated patients and 2) before pandemic and after influenza A/H1N1pdm09 infection, in patients presented natural infection. Results: At baseline, 3% of 59 recipients of adjuvanted vaccine and 0% of 20 infected patients were seroprotected (antibody titer ≥ 1/40). Seroprotection rate observed 42 days after vaccination was not different from that observed after natural infection (66% and 60% respectively, p = 0.78). In vaccinated patients, seroprotection rate increased significantly from 54% to 66% between day 21 and 42 (p = 0.015). Moreover, after 6 months, seroprotection rate in 21 vaccinated patients was similar to that observed in 10 infected patients evaluated at least 76 days after infection (D76-217) (60% and 81% respectively, p = 0.2). In multivariate analysis, no immunosuppressive treatment or chronic graft-versus-host disease (GVHD) and longer time between transplantation and vaccination/infection were associated with a stronger humoral response. The adjuvanted vaccine was safe with low rate of GVHD worsening. Conclusion: In HSCT recipients, two doses of influenza A/H1N1pdm09 adjuvanted vaccine were safe and induced a humoral response comparable to that triggered by natural infection in these patients.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Immunité humorale</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Humoral immunity</s0><s5>05</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Inmunidad humoral</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Adjuvant immunologique</s0><s5>06</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Immunological adjuvant</s0><s5>06</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Cellule souche</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Stem cell</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Célula primitiva</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Receveur</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Recipient</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Receptor</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Vaccination</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Vaccination</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Vacunación</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Cellule hématopoïétique</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Hematopoietic cell</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Célula hematopoyética</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Transplantation</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Transplantation</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Trasplantación</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Grippe A</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Influenza A</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Gripe A</s0><s5>14</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Réponse immune</s0><s5>67</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Immune response</s0><s5>67</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Respuesta inmune</s0><s5>67</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fN21><s1>104</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001C78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:14-0076696
|texte= Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients
}}
| This area was generated with Dilib version V0.6.34. |  |